ABT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
12.6B
+12.8%
11.2B
-2.6%
11.5B
+0.8%
11.4B
+2.0%
11.1B
Cost of Revenue
5.3B
+8.9%
4.9B
-0.7%
4.9B
-3.0%
5.1B
+4.6%
4.9B
Gross Profit
7.3B
+15.8%
6.3B
-4.0%
6.5B
+3.9%
6.3B
+0.1%
6.3B
Operating Expenses
5.6B
+13.1%
4.9B
+15.0%
4.3B
+1.2%
4.2B
+0.0%
4.2B
R&D
892.0M
+16.3%
767.0M
+4.4%
735.0M
-4.0%
766.0M
+5.7%
725.0M
SG&A
4.0B
+7.6%
3.7B
+19.5%
3.1B
+2.6%
3.1B
-1.3%
3.1B
Operating Income
1.7B
+25.9%
1.3B
-40.2%
2.3B
+9.4%
2.1B
+0.2%
2.1B
EBITDA
2.8B
+28.2%
2.1B
-29.4%
3.0B
+6.8%
2.8B
+0.7%
2.8B
Net Income
928.0M
-13.8%
1.1B
-39.4%
1.8B
+8.0%
1.6B
-7.6%
1.8B
EPS (Basic)
$0.53
-14.5%
$0.62
-38.0%
$1.00
+6.4%
$0.94
-7.8%
$1.02
EPS (Diluted)
$0.53
-13.1%
$0.61
-40.8%
$1.03
+9.6%
$0.94
-6.9%
$1.01
Shares (Diluted)
1.7B
-0.2%
1.7B
+1.8%
1.7B
-1.9%
1.7B
-0.1%
1.8B
Abbott Laboratories (ABT) โ€” Financials